pimobendan has been researched along with Death, Sudden, Cardiac in 5 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output." | 6.38 | Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 5.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine." | 3.77 | Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011) |
| "In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output." | 2.38 | Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 1.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nonaka, M | 1 |
| Morimoto, S | 2 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Li, L | 1 |
| Wang, YY | 2 |
| Arioka, M | 1 |
| Yoshihara, T | 1 |
| Takahashi-Yanaga, F | 2 |
| Sasaguri, T | 2 |
| de Madron, E | 1 |
| King, JN | 1 |
| Strehlau, G | 1 |
| White, RV | 1 |
| Du, CK | 1 |
| Nishii, K | 1 |
| Minakami, R | 1 |
| Ohta, M | 1 |
| Tadano, N | 1 |
| Lu, QW | 1 |
| Zhan, DY | 1 |
| Mochizuki, M | 1 |
| Kita, S | 1 |
| Miwa, Y | 1 |
| Iwamoto, T | 1 |
| Ohtsuki, I | 1 |
| Solaro, RJ | 1 |
| Hagemeijer, F | 1 |
1 review available for pimobendan and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
Topics: Animals; Calcium; Death, Sudden, Cardiac; Heart Failure; Hemodynamics; Humans; Myocardial Contractio | 1993 |
4 other studies available for pimobendan and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D | 2015 |
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden, | 2011 |
Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |
Translational medicine with a capital T, troponin T, that is.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |